Valirx plc (VAL) ORD GBP0.001
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
ValiRx shares tank on £1.6m fundraising plan to support R&D
9 December 2024 09:43
(Sharecast News) - Shares in life sciences firm ValiRx plummeted on Monday after the AIM-listed firm announced plans to raise £1.57m to increase its R&D efforts as it continues the development of breast...
-
ValiRx subsidiary makes first sale
18 November 2024 14:04
(Sharecast News) - ValiRx, a life science company focussed on early-stage cancer therapeutics and women's health, announced the first sale from its wholly-owned subsidiary Inaphaea BioLabs on Monday.
-
ValiRx losses narrow in first half
27 September 2024 11:33
(Sharecast News) - ValiRx, a life science company focussed on cancer therapeutic development, reported a total comprehensive loss of £0.97m for the six months ended 30 June on Friday, narrowing from a...
-
ValiRx pulls out of University of Barcelona collaboration
26 September 2024 12:05
(Sharecast News) - ValiRx said in an update on Thursday that it has concluded its evaluation project with the University of Barcelona, focussed on early-stage cancer therapeutics targeting the...
-
ValiRx subsidiary inks agreement with research firm Xenopat
18 September 2024 12:48
(Sharecast News) - London-based life science company ValiRx has announced that its wholly-owned subsidiary, Inaphaea BioLabs, has entered into an evaluation and commercial use agreement with Spanish contract...
-
ValiRx inks deal with Dundee Drug Discovery Unit
12 February 2024 12:59
(Sharecast News) - ValiRx announced the signing of a significant agreement with the University of Dundee and its Drug Discovery Unit (DDU) on Monday.
-
ValiRx enters option deal with Ambrose Healthcare
5 December 2023 15:08
(Sharecast News) - Cancer therapeutics-focussed life science company ValiRx announced on Tuesday that its subsidiary ValiSeek has entered into an exclusive option agreement with Ambrose Healthcare, a private...
-
ValiRx enters partnership with StingRay Bio
10 November 2023 10:32
(Sharecast News) - Life science company ValiRx announced a new partnership with StingRay Bio on Friday, aiming to explore a promising lead series of drug candidates designed for oncology applications.
-
ValiRx shares jump as H1 losses shrink
24 August 2023 09:59
(Sharecast News) - Shares in ValiRx jumped nearly on Thursday after the biotech posted results for its first half, in which losses per share shrunk by a third.
-
ValiRx subsidiary Inaphaea signs deal with Agility Life Sciences
14 August 2023 09:53
(Sharecast News) - Life science company ValiRx announced on Monday that its wholly-owned subsidiary Inaphaea BioLabs has entered a collaborative services agreement with Agility Life Sciences.
-
ValiRx terminates collaboration with Hokkaido University
16 June 2023 11:14
(Sharecast News) - Life science company ValiRx has officially concluded its evaluation agreement with Hokkaido University, it announced on Friday.
-
ValiRx acquires assets of in-liquidation Imagen Therapeutics
14 June 2023 14:37
(Sharecast News) - Life science company ValiRx has successfully completed the acquisition of the scientific assets of Imagen Therapeutics, it announced on Wednesday.
Company announcements Announcements
-
Posting of Circular and Notice of General Meeting
10 December 2024 15:03
Valirx
-
Conditional Fundraising & Launch of Broker Offer
9 December 2024 07:00
Valirx
-
Inaphaea award of HEIF Funding and PhD sponsorship
22 November 2024 07:00
Valirx
-
Update on proposed sub-license of VAL401
20 November 2024 07:00
Valirx
-
Contract Award
19 November 2024 07:00
Valirx
-
First Sale of New Product Line
18 November 2024 07:00
Valirx
-
Update on proposed sub-license of VAL201
30 October 2024 07:00
Valirx
-
Directorate Change
18 October 2024 07:00
Valirx
-
Inaphaea Co-Marketing Agreement
7 October 2024 07:00
Valirx
-
Half-year Report
27 September 2024 07:00
Valirx
-
Conclusion of Evaluation Project
26 September 2024 07:00
Valirx
-
Inaphaea Co-Marketing Agreement
24 September 2024 07:00
Valirx
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.